PROK250117C7500
- 0.01
- 0.000.00%
ProKidney Newsroom
Cautiously Optimistic: ProKidney's Hold Rating Amid Accelerated Pathway and Trial Developments
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
One ProKidney Insider Raised Their Stake In The Previous Year
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
ProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth Plans
Morgan Stanley Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
ProKidney's Progress in FDA Approval and Financial Health
ProKidney | 10-Q: Q3 2024 Earnings Report
ProKidney GAAP EPS of -$0.14
ProKidney | 8-K: ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
ProKidney Reports Q3 EPS (14c), Consensus (15c)
ProKidney 3Q Loss $17.9M >PROK
Express News | ProKidney Corp: Qtrly Shr Loss $0.14
Express News | ProKidney Corp: Cash and Cash Equivalents Supporting Operations Into 2027
Express News | ProKidney Q3 Operating Income USD -48.973 Million Vs. IBES Estimate USD -44.3 Million
ProKidney Reports Third Quarter 2024 Financial Results Along With Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
ProKidney to Present Cell Therapy Data for CKD at ASN Kidney Week 2024